Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
January 14, 2002
- Price Cutting Rates for Long-listed Drugs Likely to Be 3-tiered
January 14, 2002
- Vital-Net to Acquire Shares of Inoue Seishodo
January 14, 2002
- Home Caregivers of Dementia Patients under Severe Stress: Eisai, Pfizer Seminar
January 14, 2002
- Korosho Budget Totals \18,668.4 Bil., Up 3.2%
January 14, 2002
- Fukujin Takes Over Ethical Drugs, Lab Reagents from Inagaki
January 14, 2002
- Business Improves for Local Government-managed Hospitals
January 14, 2002
- 6 Products Including Flutide 200 Diskus Added to NHI List
January 14, 2002
- 9 Wholesalers Accept FTC Recommendation: Cartel Affair in Tohoku
January 14, 2002
- LDP to Review Operations of Univ., Social Insurance Hospitals
January 14, 2002
- OPSR, PMDEC to Be Merged: Administrative Reform
January 14, 2002
- GSK's Flutide Diskus Included in NHI Price List
December 31, 2001
- The Year 2001 in Retrospect:
December 31, 2001
- BUSINESS NEWS IN BRIEF
December 31, 2001
- Innovation and Reward - Contributing to a Healthy and Growing Economy
December 31, 2001
- Takara Shuzo Develops New Gene Transfer Technology, rPIC Method
December 31, 2001
- Perspective for 2002
December 31, 2001
- J&J: New Breast Cancer Biopsy System
December 31, 2001
- Disasters That Never Come
December 31, 2001
- Sugi Pharmacy to Maintain 30% Growth Rates
December 31, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…